We conduct experimental trials into Mesothelioma and Lung Cancer.

Our current clinical trials are:

Immunotherapy of mesothelioma and lung cancer.
This trial involves the use on autologous tumour, obtained following surgical resection, administered as a vaccine subcutaneously 2-weekly with recombinant GM-CSF given on days 1-3 for a six month period. This is entirely and outpatient procedure but all patients need to be resident in Perth for their 2-weekly visits over a period of 4-6 months and must have operable disease on clinical grounds.

Detailed protocol with references
Consent forms
Patient information sheet
 

For more information contact:

jolghazi@cyllene.uwa.edu.au